Falavolti Cristina, Sergi Federico, Shehu Ervin, Buscarini Maurizio
Department of Urology, Campus Bio-Medico University of Rome, Rome, Italy,
World J Surg. 2013 Dec;37(12):2950-5. doi: 10.1007/s00268-013-2199-y.
Rectourinary fistula (RUF) is an uncommon but devastating condition in men. It usually occurs as a complication of prostatic cancer treatment, whether this is by radiation therapy or surgery. It can also occur in patients with benign pathology of the prostate, inflammatory bowel disease, or Fournier's gangrene, and following pelvic trauma. RUF represents a challenge for the surgeon because spontaneous closure is a rare event. Several techniques have been described for surgical repair of fistula. The goal of the present study was to demonstrate that the York Mason posterior, transrectal correction of an iatrogenic RUF is a reliable approach that offers good postoperative outcomes.
We retrospectively reviewed the medical records of 39 patients who underwent York Mason repair from 1998 to 2012 at the University of Southern California (USC) and Campus Bio-Medico University of Rome (UCBM). The most frequent common causes of RUF were itemized, and statistical analysis was performed to determine correlations between the fistula's etiology and surgical outcome. Patients were then divided into two different cohorts: those who had undergone only one previous procedure (group 1) and those who had undergone two or more surgeries (group 2). We performed a statistical analysis between the two groups and calculated the percentage of fistula repair by means of the posterior trans-sphincteric approach with the York Mason technique in each groups We evaluated the presence of comorbidities (diabetes and infection) and their influence on the surgical outcome. Finally, we reported patient outcomes during follow-up.
In the present series, the RUF was iatrogenic in every case. The onset of the fistula followed prostate cancer treatment, most commonly after laparoscopic procedures. The success rate of fistula repair was found to be independent of the fistula's etiology. Diabetes and infections did not influence the surgical outcome. Overall, more than 50 % of patients treated with the York Mason posterior, transanal, transrectal approach remained free of fistula during follow-up. Almost 90 % of those who were previously operated only once remained free of fistula.
The posterior trans-sphincteric approach of the York Mason technique is effective in treating RUF.
直肠尿道瘘(RUF)在男性中虽不常见但后果严重。它通常作为前列腺癌治疗的并发症出现,无论是通过放射治疗还是手术。它也可发生于前列腺良性病变、炎症性肠病或福尼尔坏疽患者以及骨盆创伤后。RUF对外科医生来说是一项挑战,因为自发闭合很少见。已有多种瘘管手术修复技术被描述。本研究的目的是证明约克·梅森经直肠后路修复医源性RUF是一种可靠的方法,术后效果良好。
我们回顾性分析了1998年至2012年在南加州大学(USC)和罗马生物医学大学校园(UCBM)接受约克·梅森修复术的39例患者的病历。列出了RUF最常见的病因,并进行统计分析以确定瘘管病因与手术结果之间的相关性。然后将患者分为两个不同队列:仅接受过一次先前手术的患者(第1组)和接受过两次或更多次手术的患者(第2组)。我们对两组进行了统计分析,并计算了每组采用约克·梅森技术经括约肌后入路修复瘘管的百分比。我们评估了合并症(糖尿病和感染)的存在及其对手术结果的影响。最后,我们报告了随访期间患者的结果。
在本系列中,每例RUF均为医源性。瘘管发生于前列腺癌治疗后,最常见于腹腔镜手术后。发现瘘管修复成功率与瘘管病因无关。糖尿病和感染不影响手术结果。总体而言,采用约克·梅森经肛门、经直肠后路治疗的患者中,超过50%在随访期间无瘘管。之前仅接受过一次手术的患者中,近90%无瘘管。
约克·梅森技术的经括约肌后入路治疗RUF有效。